Lisa Martinez

Pharma Business Analyst

Former pharmaceutical business development executive with 12 years of experience covering drug commercialization, patent landscapes, and biopharma M&A activity. Previously worked at popluar pharma companies before becoming a specialist journalist focused on pharmaceutical market dynamics, pricing strategies, and the business challenges of bringing new medicines to market. Expert in analyzing pipeline valuations and competitive positioning.

AI Author, more information here

Johnson & Johnson: 2025 Trading Upside, Biotech M&A Boost, and Strategic Growth Outlook

Johnson & Johnson’s latest trading session shows modest gains amid cautious optimism. Explore how portfolio diversification, patent cliffs, and strategic M&A drive J&J’s growth prospects.

Lisa Martinez

30/06/2026, 10:59

4 minutes to read

How Eli Lilly Is Using AI & Strategic Acquisitions to Beat Patent Cliffs and Outsmart Competitors

Explore how Eli Lilly’s AI‑driven R&D and targeted acquisitions are reshaping its pipeline, cutting costs, and battling patent cliffs in a competitive pharma market.

Lisa Martinez

29/06/2026, 14:57

4 minutes to read

AbbVie’s $109 B Apogee Acquisition Boosts Gene‑Therapy Pipeline and Market Position in 2026

AbbVie’s $109 billion Apogee Therapeutics deal boosts gene‑therapy pipelines, offsets patent cliffs, and strengthens its market moat, positioning it for sustained growth in 2026.

Lisa Martinez

29/06/2026, 10:00

3 minutes to read

How Daiichi Sankyo’s €1 Billion German Expansion Secures European Pharma Dominance

Explore how Daiichi Sankyo’s €1 billion investment in Germany boosts its EU market‑access, tackles patent cliffs, and fuels biologics innovation.

Lisa Martinez

28/06/2026, 23:56

4 minutes to read

Revolution Medicines CFO Trades Shares, Net Gain of $33,720 – Routine Portfolio Management Explained

Revolution Medicines CFO’s recent insider trades show routine portfolio moves, with a net 4% gain—no strategic shift, just standard 10(b)(5)(1) activity.

Lisa Martinez

28/06/2026, 19:09

2 minutes to read

Merck KGaA’s Earnings Reveal Strong Pricing Power, Supply Leverage and Growth‑Focused M&A in Pharma’s Shifting Landscape

Merck KGaA’s latest earnings reveal how strong revenue visibility, supply agreements, and strategic acquisitions—like Bio‑Techne—enable pharma to navigate patent cliffs, market access, and high‑growth oncology pipelines while safeguarding margins.

Lisa Martinez

28/06/2026, 17:00

5 minutes to read

How Lupin’s Tentative FDA Approval of Enzalutamide Could Shake Up U.S. Oncology Pricing

Explore how Lupin Limited’s tentative FDA approval for generic enzalutamide could reshape the U.S. oncology market, boost revenue, and spark new M&A opportunities.

Lisa Martinez

28/06/2026, 05:03

4 minutes to read

AbbVie’s SKYRIZI Pediatric Approval & $10.9B Apogee Deal: A Smart Move to Beat Patent Cliffs

AbbVie’s new pediatric SKYRIZI approval and $10.9 bn Apogee acquisition give the drugmaker a fresh, high‑growth immunology pipeline that buffers patent cliffs and targets premium pricing in psoriasis, AD and pediatrics.

Lisa Martinez

28/06/2026, 02:14

4 minutes to read

How Lupin’s Generic Xtandi® Could Shake Up the U.S. Oncology Market

Explore how Lupin’s tentative FDA approval of generic Xtandi® could reshape the prostate‑cancer market, boost patient access, and impact Astellas’ revenue.

Lisa Martinez

27/06/2026, 01:39

4 minutes to read

Supreme Court Ruling Boosts Bayer’s Profitability, Cuts $1.2 Billion Litigation Risk

Supreme Court ruling lifts Bayer’s legal risk on Round Up, boosting its U.S. herbicide market share, cutting litigation costs, and freeing capital for pharma and crop‑science innovation.

Lisa Martinez

26/06/2026, 13:09

4 minutes to read

Newer articles Older articles